Clindamycin Phosphate / Benzoyl Peroxide Gel — Competitive Intelligence Brief

Clindamycin Phosphate / Benzoyl Peroxide Gel (Clindamycin Phosphate / Benzoyl Peroxide Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic combination. Area: Dermatology.

phase 3 Topical antibiotic combination Bacterial ribosome (clindamycin); oxidative antimicrobial mechanism (benzoyl peroxide) Dermatology Small molecule

Target snapshot

Clindamycin Phosphate / Benzoyl Peroxide Gel (Clindamycin Phosphate / Benzoyl Peroxide Gel) — Watson Laboratories, Inc.. Clindamycin reduces acne-causing bacteria while benzoyl peroxide provides antimicrobial and keratolytic effects to treat acne vulgaris.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clindamycin Phosphate / Benzoyl Peroxide Gel TARGET	Clindamycin Phosphate / Benzoyl Peroxide Gel	Watson Laboratories, Inc.	phase 3	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative antimicrobial mechanism (benzoyl peroxide)
Benzoyl peroxide with clindamycin	Benzoyl peroxide with clindamycin	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosomes (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Duac® fixed dose combination gel	Duac® fixed dose combination gel	GlaxoSmithKline	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Polysporin Ointment	Polysporin Ointment	University of British Columbia	marketed	Topical antibiotic combination	Bacterial cell wall (bacitracin) and bacterial cell membrane (polymyxin B)
clindamycin 1% / benzoyl peroxide 5% tube	clindamycin 1% / benzoyl peroxide 5% tube	Sanofi	marketed	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Clindamycin and BPO 5% gel	Clindamycin and BPO 5% gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination with keratolytic agent	Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic combination class)

1. Stiefel, a GSK Company · 3 drugs in this class
2. GlaxoSmithKline · 3 drugs in this class
3. GWT-TUD GmbH · 2 drugs in this class
4. Sun Pharmaceutical Industries, Inc. · 1 drug in this class
5. University Health Network, Toronto · 1 drug in this class
6. University of British Columbia · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. B. Braun Medical SA · 1 drug in this class
9. Watson Laboratories, Inc. · 1 drug in this class
10. Padagis LLC · 1 drug in this class